What is the role of leukotriene modifiers in asthma treatment?

Leukotriene modifiers play a significant role in the management of asthma by helping to reduce inflammation and bronchoconstriction. These medications work by blocking the effects of leukotrienes, which are inflammatory substances released by the immune system that contribute to the symptoms of asthma, such as airway swelling and increased mucus production. By inhibiting these substances, leukotriene modifiers can effectively decrease airway inflammation, improve airflow, and reduce the frequency of asthma attacks.

In contrast, immediate symptom relief in asthma is typically provided by bronchodilators, specifically short-acting beta-agonists, not leukotriene modifiers. Additionally, leukotriene modifiers do not increase airway resistance; rather, they help to improve airway function. They are also used as a long-term treatment option to manage asthma and are not intended solely for use during acute asthma attacks. This long-term management approach aligns with their role in controlling asthma symptoms and preventing exacerbations, making them an essential part of comprehensive asthma care.